At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 555 enrolled
Drug / intervention
marimastat +1 moredrug
Likely dose
marimastat 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study of Marimastat in Patients With Small Cell Lung Cancer Following a Response to First Line Chemotherapy
In Brief
A Phase 3 clinical trial evaluating marimastat and Placebo for Lung Cancer. Completed, enrolled 555 participants across 38 sites.
Detailed Summary
RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of marimastat with a placebo following chemotherapy in treating patients who have small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1997
Primary CompletionFeb 2001
First PostedFeb 2004
Study CompletionDec 2008
TodayJul 2026
First PostedFeb 16, 2004
Enrollment StartJan 31, 1997
Primary CompletionFeb 13, 2001
Study CompletionDec 15, 2008
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 22.4 years ago
Interventions
marimastatdrug
10 mg PO BID
Placebodrug
10 mg PO BID